Showing posts with label FDA. Show all posts
Showing posts with label FDA. Show all posts

Monday, 23 March 2020

Nigeria records chloroquine poisoning after Trump endorses it for coronavirus treatment

Health officials in Nigeria have issued a warning over chloroquine after they said three people in the country overdosed on the drug, in the wake of President Trump's comments about using it to treat coronavirus.

A Lagos state official told CNN that three people were hospitalized in the city after taking the drug. Officials later issued a statement cautioning against using chloroquine for Covid-19 treatment.
US President Donald Trump claimed at a White House briefing last week that the Food and Drug Administration had approved the "very powerful" drug chloroquine to treat coronavirus.

"It's shown very encouraging -- very, very encouraging early results. And we're going to be able to make that drug available almost immediately. And that's where the FDA has been so great. They -- they've gone through the approval process; it's been approved. And they did it -- they took it down from many, many months to immediate. So we're going to be able to make that drug available by prescription or states," Trump said.

He added: "Normally the FDA would take a long time to approve something like that, and it's -- it was approved very, very quickly and it's now approved, by prescription."

However, the FDA after the briefing issued a statement saying it had not approved the drug for use against Covid-19 and is still studying its effectiveness against the disease.

Price hikes
Trump's endorsement of the drug led to a surge of interest among Nigerians keen to stock up on the medication, which has led to inevitable price hikes in the megacity of around 20 million inhabitants.

One man told CNN that in a pharmacy near his home on the Lagos mainland, he witnessed the price rise by more than 400% in a matter of minutes.

Kayode Fabunmi, a Lagos-based lawyer, said: "The pharmacist knew the market and was saying to every incoming customer, 'You know Donald Trump has said this thing cures coronavirus,' and the price kept changing.

"The original price was 200 naira (around 50 cents), then it became 500 naira ($1.38) then it became 1,000 naira ($2.77) while I was there," he said.

The Lagos State Health Ministry issued a brief statement saying there was no "hard evidence that chloroquine is effective in prevention or management of coronavirus infection."

Chloroquine is used to treat malaria, lupus and rheumatoid arthritis.

Malaria is an endemic disease in Nigeria and other parts of Africa and for many years, it was common to treat it with chloroquine. However, at least 40 African countries, including Nigeria, have phased it out as a frontline antimalarial drug and replaced it with other drugs following widespread resistance to it.

Lack of clinical evidence
While doctors in China, the United States and other countries have used the drug experimentally in Covid-19 patients, there is not yet enough clinical evidence that it's effective in humans or the management of the disease.

Dr. Michel Yao, Africa emergency response program manager for the World Health Organization, told CNN there are 20 drugs and the same number of vaccines under clinical trial, and it is too early to make recommendations about the efficacy of any for the treatment of the virus.

"The WHO's position is clear. Any medication should be based on evidence. We don't have yet any evidence from any of these trials that would allow WHO to do a formal recommendation. All these are in progress, so it is difficult for us to recommend at this stage that any of the medicine can be of use for the treatment of coronavirus," Yao said.

"It is too early to rush to the decision that chloroquine ... at least for WHO to recommend it for the treatment of coronavirus," he added.

Side effects
Fabunmi, 44, told CNN he had used chloroquine before to treat malaria and recalled that severe itching was one of the side effects.

"For two, three days you will be itching," he said. "You dread having a bath, you will scratch and scratch and you would have to take piriton (an antihistamine) alongside it.

"It's also very bitter. If you make the mistake of letting it drop in your mouth, you will feel the taste for a long time."
Nigeria as of Sunday has reported 30 cases of Covid-19 and Fabunmi said he feels better having his batch of chloroquine.

"I didn't mind paying as I just wanted to get some in case it will become necessary. ... I didn't want a situation where I will regret not buying it. Better to be safe than sorry," he said.

(Source: CNN)

Tuesday, 29 May 2018

FDA approves preventive migraine treatment

Migraine sufferers across the United States have their eyes on a newly approved drug that's offering hope for reducing the frequency of monthly migraine attacks.

On Thursday, the US Food and Drug Administration approved Aimovig for the preventive treatment of migraines in adults with episodic or chronic migraines. Episodic migraine is when symptoms occur zero to 14 days each month; symptoms of chronic migraine occur 15 days or more a month.

Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, or CGRP, a molecule that is involved in migraine attacks. Aimovig targets that molecule's receptor in your body.

The treatment, administered through monthly self-injections, requires a prescription and could be available to patients within a week. Aimovig is expected to cost $575 monthly or $6,900 annually in the United States.

There are three other migraine treatments in this newly emerging class of drugs.
Aimovig is administered through monthly self-injections.
Those drugs target the CGRP molecule itself, instead of its receptor. They are experimental but, if approved, might be made available to patients as early as this fall for one and next year for the others, said Dr. Stewart Tepper, director of the Dartmouth Headache Center at Dartmouth-Hitchcock Medical Center in New Hampshire, who was a clinical investigator in the Aimovig trials.

"When CGRP is released, outside of the brain, it causes inflammation and blood vessel dilation -- the blood vessels get big -- and that combination of inflammation and blood vessels getting big is the pain of migraine," said Tepper, who is also a professor of neurology at the Geisel School of Medicine at Dartmouth College.

Migraine is three times more common in women than in men and affects more than 10% of people worldwide, the FDA noted. In the US, about 12% of the population gets migraine headaches.

What was found in clinical trials
The effectiveness of Aimovig was evaluated in three key clinical trials.

The first included 955 people with a history of episodic migraine. Over the course of six months, those who received the treatment experienced one or two fewer monthly migraine days, on average, compared with a placebo.

The second study included 577 patients with a history of episodic migraine. Over the course of three months, those who received Aimovig treatment experienced one fewer migraine day per month.

The third study evaluated 667 patients with a history of chronic migraine. Over the course of three months, patients treated with Aimovig experienced, on average, 2½ fewer monthly migraine days than those receiving a placebo.

"It may not get rid of all of them, but it really dramatically improves the frequency, severity and duration of the migraine attacks," Tepper said of the new treatment.

Patients "still will need to take something when they get a migraine attack, but this is the first designer medication to prevent migraine rather than treat as needed," he said.

In the clinical studies, the most common adverse side effects were pain at the injection site and constipation. The drug can be injected in the thigh, the abdomen or the outer area of the upper arm.

"The field is excited about a new drug that is specifically targeted for migraine mechanisms," said Dr. Teshamae Monteith, assistant professor of clinical neurology at the University of Miami and a member of the American Academy of Neurology, who was not involved in the development of the drug.

"Not only does the data show that it's effective for people who have what we call episodic migraine, but it's also effective for people who have chronic migraine," Monteith said.

"If you can imagine, a patient with chronic migraine has at least 15 days -- half the month -- with some type of headache, and eight days out of that month, it's what you would call a moderate to severe headache with associated symptoms, such as light sensitivity, sound sensitivity, some cognitive dysfunction, [gastrointestinal] symptoms and sometimes visual and motor symptoms," she said. "Patients can have fatigue, concentration impairment, neck stiffness and sometimes mood changes as well."

By Friday, Monteith was already receiving requests for prescriptions and questions about Aimovig from her patients, including Helene Good, who uses injections of Botox to treat her migraines.

'It's really exciting'
"I first heard about it when it showed up on my phone this morning as an article in my news, and I just happened to be on my way to see Dr. Monteith for my treatment today," Good said Friday.

"I read it to my spouse on the way over, and it's really exciting," said Good, a 63-year-old Miami resident who has had migraines since she was in her late teens.

"It's not like just having a bad headache. For me, it manifests in other ways," she said. "One side of my face droops, which sort of looks like I've had a mini stroke. I'm a pretty fast speaker, but my speech gets very slow."

When it comes to migraine treatment options, "you're always hoping and looking for hope," she said.
Treatment options for migraine sufferers typically depend on the frequency and severity of the migraine attacks. Patients who have episodic migraine usually rely on pain medications to treat the migraine pain. To avoid episodes, some patients may stay away from triggers, such as certain foods, lack of sleep or stress.

Before Aimovig, "the FDA-approved preventive medications for episodic migraine were only four. Two of them are beta blockers, anti-blood pressure medicines, and two of them are anti-epilepsy drugs," Tepper said.

"There was one FDA-approved treatment for chronic migraine, which was Botox," he said. For patients, "with our current preventive medicines, they have to take oral medicine every day, with the exception of Botox, which is given in 31 injections every 12 weeks."

Yet a problem with many of those other treatment options is that some are traditionally used for other disorders and have side effects, Monteith said.

"Not only are some of the drugs not effective for every patient, but then there's this issue with tolerability," she said. "Some of these drugs are not well-tolerated. In the right person, it's great, but certainly we need some other option."


Additionally, there are medical devices such as a FDA-approved nerve-stimulating "tiara" called Cefaly, another nerve-stimulating device called gammaCore and even an approach called transcranial magnetic stimulation. Some patients have turned to acupuncture for migraine therapy.

"As a headache specialist, there are a number of treatments that are available for our patients preventively for migraine, but many of them are associated with a lot of different side effects, and we've been waiting for the day when we can have a medication that specifically targets migraine and prevents it in this unique modality and is associated with few side effects," said Dr. Thomas Berk, headache neurologist at NYU Langone Health, who was not involved in the development of the new treatment.

"I've had a number of requests already from patients asking, is it possible to get it to them quickly? What are the ways of getting it, and the big question being, is my insurance going to cover it, which is a question that we don't really know particularly yet," he said. "Everyone's excited about it."

(Source: CNN)